Home » Stocks » Can-Fite BioPharma

Can-Fite BioPharma Ltd. (CANF)

Stock Price: $1.74 USD -0.03 (-1.69%)
Updated Oct 23, 2020 4:00 PM EDT - Market closed
Pre-market: $1.84 +0.10 (5.75%) Oct 26, 5:09 AM

Stock Price Chart

Key Info

Market Cap 26.79M
Revenue (ttm) 580,571
Net Income (ttm) -9.59M
Shares Out 15.40M
EPS (ttm) -2.22
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 23, 2020
Last Price $1.74
Previous Close $1.77
Change ($) -0.03
Change (%) -1.69%
Day's Open 1.75
Day's Range 1.72 - 1.78
Day's Volume 112,271
52-Week Range 1.08 - 4.95

More Stats

Market Cap 26.79M
Enterprise Value 26.02M
Earnings Date (est) Nov 25, 2020
Ex-Dividend Date n/a
Shares Outstanding 15.40M
Float n/a
EPS (basic) n/a
EPS (diluted) -2.22
FCF / Share -2.29
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 333,102
Short Ratio 0.80
Short % of Float n/a
Beta 1.55
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 46.15
PB Ratio 3.06
Revenue 580,571
Operating Income -3.43M
Net Income -9.59M
Free Cash Flow -3.09M
Net Cash 777,714
Net Cash / Share 0.05
Gross Margin 100.00%
Operating Margin -590.70%
Profit Margin -471.80%
FCF Margin -531.64%
ROA -73.23%
ROE -146.95%
ROIC -513.50%
Key stats in USD, based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (2)

Buy 2
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(187.36% upside)
Current: $1.74
Target: 5.00
*Average 12-month USD price target from 2 stock analysts.

Financial Performance

Financial numbers in millions ILS.

Financial Overview

Revenue Growth-46.81%384.16%378.18%-74.34%-----32.49%-
Gross Profit2.033.820.790.170.64---1.792.64
Operating Income-12.00-5.41-7.19-8.68-25.04-27.77-31.31-22.43-6.62-13.35
Net Income-9.59-6.57-6.43-8.39-19.77-24.52-30.81-21.93-28.37-
Shares Outstanding2.692.221.851.841.421.051.05---
Earnings Per Share-0.22-0.34-0.38-9.00-24.30-40.50-63.60-62.40-81.60-45.00
Operating Cash Flow-10.80-4.16-8.97-8.71-18.16-28.53-30.06-16.24-20.92-12.97
Capital Expenditures--0.03-0.01-0.01-0.17-0.04-
Free Cash Flow-10.80-4.19-8.98-8.72-18.33-28.57-30.09-16.17-20.84-13.07
Cash & Equivalents2.763.893.5131.2066.0336.0920.774.2814.62-
Total Debt0.04---------
Net Cash / Debt2.723.893.5131.2066.0336.0920.774.2814.62-
Book Value0.883.025.0114.8740.2725.2413.23-2.6510.31-
Numbers in millions ILS, except per-share numbers.

Company Profile

Company Details

Full Name Can-Fite BioPharma Ltd.
Country Israel
Employees 8
CEO Pnina Fishman

Stock Information

Ticker Symbol CANF
Stock Exchange NYSE American
Sector Healthcare
Industry Biotechnology
Unique Identifier NYSEAMERICAN: CANF


Can-Fite BioPharma, a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver and inflammatory disease, and sexual dysfunction. The company's lead drug candidate CF101 (Piclidenoson), which is in Phase III clinical trial for the treatment of rheumatoid arthritis and psoriasis. It also develops CF102 (Namodenoson) that is completed Phase II clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase II trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. Can-Fite BioPharma Ltd. has collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was founded in 1994 and is headquartered in Petah-Tikva, Israel.